NCT01037881

LEO 29102 Cream in the Treatment of Atopic Dermatitis

A Phase 2, Proof of Concept and Dose Finding Study, Investigating Treatment Efficacy of LEO 29102 Cream, LEO 29102 Cream Vehicle, and Elidel® Cream 10 mg/g, After Cutaneous Administration Twice Daily for 4 Weeks

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 183 (actual)
• Sponsor: LEO Pharma · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This is a proof of concept and dose finding Phase II trial comparing 5 dose strengths with vehicle and an active comparator (Elidel cream 10 mg/g) in a 4 week, twice daily treatment regimen in mild to moderate atopic dermatitis patients.

Conditions

• Atopic Dermatitis

Interventions

Type	Name	Description
DRUG	LEO 29102	comparison of different dosages of drug
DRUG	Elidel®	comparison

Timeline

• Start date: 2009-12-01
• Primary completion: 2010-06-01
• Completion: 2010-06-01
• First posted: 2009-12-23
• Last updated: 2025-03-10
• Results posted: 2019-10-14

Locations

3 sites across 3 countries: Canada, Finland, Germany